ZA200303739B - Pet food composition and method. - Google Patents
Pet food composition and method. Download PDFInfo
- Publication number
- ZA200303739B ZA200303739B ZA200303739A ZA200303739A ZA200303739B ZA 200303739 B ZA200303739 B ZA 200303739B ZA 200303739 A ZA200303739 A ZA 200303739A ZA 200303739 A ZA200303739 A ZA 200303739A ZA 200303739 B ZA200303739 B ZA 200303739B
- Authority
- ZA
- South Africa
- Prior art keywords
- pet
- diet
- ppm
- food
- accordance
- Prior art date
Links
- 235000013305 food Nutrition 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 42
- 239000000203 mixture Substances 0.000 title claims description 30
- 235000005911 diet Nutrition 0.000 claims description 79
- 230000037213 diet Effects 0.000 claims description 77
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 63
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 50
- 235000019136 lipoic acid Nutrition 0.000 claims description 36
- 229960002663 thioctic acid Drugs 0.000 claims description 36
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 31
- 230000003340 mental effect Effects 0.000 claims description 31
- 239000003963 antioxidant agent Substances 0.000 claims description 28
- 235000006708 antioxidants Nutrition 0.000 claims description 28
- 230000003078 antioxidant effect Effects 0.000 claims description 27
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 24
- 229930003268 Vitamin C Natural products 0.000 claims description 24
- 235000019154 vitamin C Nutrition 0.000 claims description 24
- 239000011718 vitamin C Substances 0.000 claims description 24
- 241000282465 Canis Species 0.000 claims description 20
- 241000282324 Felis Species 0.000 claims description 18
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 17
- 229930003427 Vitamin E Natural products 0.000 claims description 15
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 235000019165 vitamin E Nutrition 0.000 claims description 15
- 239000011709 vitamin E Substances 0.000 claims description 15
- 229940046009 vitamin E Drugs 0.000 claims description 15
- 229960001518 levocarnitine Drugs 0.000 claims description 13
- 235000016709 nutrition Nutrition 0.000 claims description 12
- 230000006866 deterioration Effects 0.000 claims description 10
- 229960004203 carnitine Drugs 0.000 claims description 7
- 230000004792 oxidative damage Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- -1 1- carnitine Chemical compound 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 30
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 27
- 108010053070 Glutathione Disulfide Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 14
- 229960003180 glutathione Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- QVJPPFAOCXDDPW-UHFFFAOYSA-N 5-[chloro(difluoro)methyl]-1,2-oxazole Chemical compound FC(F)(Cl)C1=CC=NO1 QVJPPFAOCXDDPW-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 244000300264 Spinacia oleracea Species 0.000 description 2
- 235000009337 Spinacia oleracea Nutrition 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 235000003687 soy isoflavones Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- OWQDWQKWSLFFFR-WDSKDSINSA-N gamma-Glu-Glu Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(O)=O)CCC(O)=O OWQDWQKWSLFFFR-WDSKDSINSA-N 0.000 description 1
- 108010085978 gamma-glutamylglutamate Proteins 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Description
COMPOSITION AND METHOD
Companion animals such as dogs and cats seem to suffer from aging problems. Some of these are manifested in commonplace sayings. One of these is “You can’t teach an old dog new tricks”. This saying arises from the observation that as dogs age, their mental capacity seems to diminish as well as physical abilities. Mental activities associated with thinking learning and memory seem to be lessened (Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW 1996: The canine as an animal model of aging and dementia;
Neurobiology of aging 17:259-268). Additionally, behavioral change can be manifested in the aging animals in association with the changing mental capacity. Many causes have been assigned to this lessening of capacity.
These losses in capacity are generally observed in aged canines and felines. Dogs of seven years or older and felines of seven years or older are considered aged and can experience this problem.
The presence of significant levels of at least one antioxidant in the diet of an adult companion pet or fed to a pet outside his diet can inhibit the onset of deterioration of the mental capacity of the aged companion pet and/or maintain the mental capacity of the adult . companion pet further into the aged years. ' Summary of the Invention
In accordance with the invention, there is a companion pet diet . meeting ordinary nutritional requirements of an adult pet and further comprising a sufficient amount of an antioxidant or mixture thereof to . inhibit the onset of deterioration of the mental capacity of said companion pet in its aged years.
A further aspect of the invention is a method for inhibiting the deterioration of the mental capacity of an aged companion pet, which comprises feeding said pet in his adult years an antioxidant or mixture thereof at sufficient levels to accomplish this inhibition.
In further accordance with the invention is a companion adult pet diet meeting ordinary nutritional requirements of an adult companion pet and further comprising an antioxidant selected from the group consisting of Vitamin E, vitamin C, alpha-lipoic acid, I- carnitine and any mixtures thereof in quantities sufficient to inhibit the deterioration of the mental capacity of said pet in its aged years.
A still further aspect of the invention is a method for increasing the mental capacity of an aged companion pet, which comprises feeding the pet in its adult years an amount of an antioxidant or mixture thereof sufficient to increase the mental capacity.
Another aspect of the invention is a method for increasing the mental capacity of an adult companion pet which comprises feeding the pet an amount of an antioxidant or mixture thereof sufficient to . increase the mental capacity of said pet. ) In all of these methods, it is desirable to administer the antioxidant or mixture thereof in the diet of the animal.
The diet fed to the adult companion pet, for example canine and . feline is the standard normal diet fed to an animal of that age. Below is a typical diet for a canine of 1 to 6 years of age.
Table 1
Protein (% of dry matter)
Fa or marie
Phosphorous (% of dry matter) 06
Soda i of dy aces
Adding significant quantities of an antioxidant or mixture thereof to the companion adult pet diet can bring about delay of the onset of demonstrative changes in the behavior, particularly the deterioration of mental capacity, as specifically shown by problem- solving capacity, in an aged pet. The term, adult, is intended to mean, in general, a canine of at least 1 to 6 years and a feline of at least 1 to 6 years. An aged dog or cat is 7 years and above.
The loss of mental capacity for canines and felines has been observed for a number of years. This loss of mental capacity is manifested in numerous ways. For a canine, for example, it can be manifested as disorientation, house soiling, altered sleep-wake patterns, decreased or altered interaction with humans and other pets, and inability to learn and concentrate. These conditions can be manifested in felines as well. Alzheimer’s, as exhibited in man, is not found in canines and felines.
Many theories have been advanced for this loss in mental capacity. To date, the inventors are unaware of any dietary course of action, which inhibits this loss of mental capacity or can actually bring about a positive change in mental capacity as measured by an objective parameter in dogs and cats.
The inventors have succeeded in accomplishing delaying the onset of this deterioration. By using the diet of their invention in adult companion pets it can be shown that aged pets mental capacity can be maintained for a longer period of time. Essentially the deterioration of mental capacity can be stopped or delayed. Memory and learning ability can be improved. Overall mental alertness can be enhanced. Age related cognitive decline could be slowed. With respect to Cognitive Dysfunction Syndrome its progress can be slowed in aged dogs and clinical signs associated with this Syndrome can be controlled. Prophylaxis where appropriate and pets in need of these components are the target group.
The component in the diet, which accomplishes this is an antioxidant or mixture thereof. An antioxidant is a material that quenches a free radical. Examples of such materials include foods such as Ginkgo Biloba, citrus pulp, grape pomace, tomato pomace, carrot and spinach, all preferably dried as well as various other materials such as beta-carotene, selenium, coenzyme QIl10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S- adenosylmethionine, glutathione, taurine, N-acetylcysteine, Vitamin . E, Vitamin C, alpha-lipoic acid, l-carnitine and the like. Vitamin E can be administered as a tocopherol or a mixture of tocopherols and ' various derivatives thereof such as esters like vitamin E acetate, succinate, palmitate, and the like. The alpha form is preferable but beta, gamma and delta forms can be included. The d form is preferable but racemic mixtures are acceptable. The forms and derivatives will function in a Vitamin E like activity after ingestion by the pet. Vitamin C can be administered in this diet as ascorbic acid . and its various derivatives thereof such as calcium phosphate salts, cholesteryl salt, 2-monophosphate, and the like which will function in a vitamin C like activity after ingesting by the pet. They can be in any form such as liquid, semisolid, solid and heat stable form. Alpha- lipoic acid can be administered into the diet as alpha lipoic acid or as a lipoate derivative as in US Patent 5,621,117, racemic mixtures, salts, esters or amides thereof. L-carnitine can be administered in the diet and various derivatives of carnitine such as the salts such as the hydrochloride, fumarate and succinates, as well as acetylated carnitine, and the like can be used.
The quantities administered in the diet, all as wt% (dry matter basis) of the diet, are calculated as the active material, per se, that is measured as free material. The maximum amounts employed should not bring about toxicity. At least about 100 ppm or at least about 150 ppm of Vitamin E can be used. A preferred range of about 500 to about 1,000 ppm can be employed. Although not necessary a maximum of about 2000 ppm or about 1500 ppm is generally not exceeded. With respect to Vitamin C at least about 50 ppm is used, desirably at least about 75 ppm and more desirably at least about 100 ppm. A nontoxic maximum can be employed. The quantity of alpha- lipoic acid can vary from at least about 25, desirably at least about 50 ppm, more desirably about 100 ppm. Maximum quantities can vary . from about 100 ppm to 600 ppm or to an amount which remains non toxic to the pet. A preferred range is from about 100 ppm to about ’ 200 ppm. For l-carnitine about 50 ppm, desirably about 200 ppm, more desirably about 300 ppm for canines are a useful minimum.
For felines, slightly higher minimums of 1-carnitine can be employed such as about 100 ppm, 200 ppm, and 500 ppm. A nontoxic maximum quantity can be employed, for example, less than about 5,000 ppm. For canines, lower quantities can be employed, for . example, less than about 5,000 ppm. For canines a preferred range is about 200 ppm to about 400 ppm. For felines a preferred range is about 400 ppm to about 600 ppm.
Beta-carotene at about 1-15 ppm can be employed.
Selenium at about 0.1 up to about 5 ppm can be employed.
Lutein at least about 5 ppm can be employed.
Tocotrienols at least about 25 ppm can be employed.
Coenzyme Q10 at least about 25 ppm can be employed.
S-adenosylmethionine at least about 50 ppm can be employed.
Taurine at least about 1000 ppm can be employed.
Soy isoflavones at least about 25 ppm can be used.
N-acetylcysteine at least about 50 ppm can be used.
Glutathione at least about 50 ppm can be used.
Gingko Biloba at least SO ppm of extract can be used.
The following are raw ingredients that are high in ORAC (Oxygen radical absorbing capacity) content. When added to the diet as 1% inclusions (for a total of 5% substitution for a low ORAC ingredient such as corn) they increased the ORAC content of the overall diet and increased the ORAC content of the plasma of the animals which ate the diet containing these components. Preferably, any ingredient with an ORAC content >25 umole of Trolox equivalents . per gram of dry matter could be used if added at 1% combination with four other 1% ingredients for a total of 5% addition to the diet. ’ Spinach pomace .
Tomato pomace
Citrus Pulp
Grape Pomace
Carrot granules
Broccoli
N Green tea
Ginkgo Biloba
Corn gluten meal
Example 1
Seventeen adult beagle dogs 2-4 years of age (control n=8, ' antioxidant-enriched n=9) were randomly placed into a control or enriched diet group. The control diet contained 59 ppm Vitamin E and < 32 ppm Vitamin C. The test diet had 900 ppm Vitamin E and 121 ppm Vitamin C, 260 ppm l-carnitine and 135 ppm alpha lipoic acid. Approximately 1 month after starting the diet, the first problem-solving task given to dogs was a landmark discrimination learning task, which is a test of spatial attention (Milgram et al., 1999
Milgram, N.W., Adams, B., Callahan, H., Head, E., Mackay, B.,
Thirlwell, C., & Cotman (1999), C.W. Landmark Discrimination
Learning in the Dog. Learning & Memory, 6:54-61).
Landmark discrimination learning requires subjects to select a particular object based on proximity to an object. The initial learning, however, is based on the dogs’ ability to learn an object discrimination task. We have previously found that the effects of age on discrimination learning depends on task difficulty.
The adult dogs on the enriched diet made fewer errors than the adult dogs on the control food when learning the landmark O test (control mean = 31.1, enriched mean = 15.1). The adult dogs proceeded on to landmark 1 and 2 testing, where the landmark is moved further away from the positive well. Adult dogs on enriched diet learned landmark 0-2 with less errors than those on the control . (number of mean errors landmark 0+1+2 control = 132.9; number of mean errors of dogs on enriched diet landmark 0+1+2=87.1).
Example 2 30 adult, random source, dogs were utilized for this study. ‘ Dogs were at lcast 10 months of age, not pregnant, not lactating and of reasonable body weight prior to start of test. Animals were randomized into 5 groups for dietary treatment with 3 males and 3 females per each group.
All dogs were fed a control food (0 ppm dl-alpha-lipoic acid added) that met or exceeded all recommendations for nutrients as proposed by the American Association of Feed Control Officials (AAFCO 2000) during a 2 week prefeeding period (Table 1). Following the prefeeding period dogs were randomized into 5 treatment groups with one of the following dl-alpha lipoic acid target-inclusions (dry matter basis): O ppm, 150 ppm, 1500 ppm, 3000 ppm, 4500 ppm. In all diets, control and alpha lipoic acid, Vitamin E was added and was present at a level of 600-1000 International Units and Vitamin C was added at levels of 100-200 ppm.
Test foods were the sole source of nutrients except for water.
Fresh water was provided ad libitum. After dogs were selected and initial body weights taken, a food dose was calculated for each dog based on the expected ME of the food. Initial food dose calculations were based on the maintenance energy requirement (MER) for the dog modified by a factor to account for normal activity as calculated by the following formula:
MER (kcal/day) = 1.6 X RER (Resting Energy Requirement)
Where: RER (kcal/day) = 70 X body weight (kg)0.75
Dogs were weighed weekly and had food doses adjusted as needed in order to feed enough food to maintain their optimal body weight. Optimal body weight was determined to be 3 on a 5 point , scale. If a dog did not maintain body weight within -10% of initial body weight, after adjustment of food dose, it was removed from the study. All measures of body weight and food intake were recorded.
Samples were ground and 0.100+ 0.001g of sample was extracted twice into 5.0 mL phosphate buffer (10mM NazHPO4, 2mM ethylenediaminetetraacetatic acid (EDTA), 0.9% NaCl, pH 7.4)*. 250 uL of extract was placed into a 5 mL glass centrifuge tube with a
Teflon lined cap. 15 pL EDTA solution (100mM EDTA, adjusted to pH 7.8 with ~1M NaOH) and 50 uL freshly prepared SmM dithioerythritol (DTE) were added. The solutions were vortexed and incubated at room temperature for 5 minutes. Then 10 pL of 1M H3PO4 and 2.0 mL diethyl ether were added. The tubes were capped, vortexed, and centrifuged at 1500 x g for 3 minutes at room temperature. The ether layer was transferred to a separate 5 mL glass centrifuge tube, while the aqueous layer was extracted twice more with 1.5 mL ether. All extractions from the same sample were combined. The extracts are then dried in a nitrogen evaporator in a water bath at room temperature. At this point, the samples were capped and frozen overnight.
The dried extracts were then thawed and reconstituted with 70 pL SDS/EDTA solution (0.11% sodium dodecyl sulfate (SDS), 15mM
EDTA, 0.9% NaCl) and 5 pL freshly prepared 1mM DTE. 50 pL of freshly prepared NaBH4 was then added to each tube. The tubes were vortexed and incubated at room temperature for 10 minutes. After 10 minutes, the samples were frozen at -70° C. Before the solutions were thawed, 20 pL 2M HCl was added. After the solutions were thawed,
800 pL. 100mM NH;:HCO3 was added. The solutions are vortexed and
S nL of 100mM momobromobimane in acetonitrile solution (mBBr) was added. The solutions were then incubated in the dark for 90 ¢ minutes at room temperature.
Excess mBBr and the DTE derivative were removed from the samples after incubation by extraction with 1.5 mL dichloromethane.
The aqueous layer was placed on the HPLC. The lipoic acid was separated using a mobile phase that consisted of 30% acetonitrile, 1% acetic acid, adjusted to pH 3.95 with ~2M NH4OH and was pumped at a flow rate of 1.0 mL/min with an isocratic elution for 15 minutes per injection. This preparation assumes that the density of the extruded food is equal to 1g/mL.
Blood was collected aseptically for complete blood count, and blood biochemistry analysis 2 weeks prior to start and again at 0, 28, 56, 84, 112, 140 and 168 days of the study. In addition, 15 ml of whole blood was collected for isolation of lymphocytes at day 0, 28 and 84 of the dietary intervention.
Heparainzed whole blood was layered onto a 50 ml Accuspin conical centrifuge tube (Sigma Chemical) and an equal volume of
Phosphate buffered saline (PBS) was added. Samples were centrifuged at at 700g for 30 minutes without brake. The monocyte layer was harvested, transferred to a 15 ml conical centrifuge tube, resuspended in 1-3 ml of PB, and centrifuged as before (First wash). : A second wash was performed as the first wash. Finally, cells were harvested and suspended in perchloric acid (10%w/v) and frozen at ~ 70C until analysis.
Samples were transferred from -70°C freezer into a cooler with dry ice in it. Vials were centrifuged at 12,000 rpm for 5 minutes in a refrigerated centrifuge. An aliquot of supernatant for glutathione (GSH) analysis was transferred to a conical test tube.
Derivatization of the acid soluble extracts was by the method of
Reed and coworkers (Fariss et al) as modified by Jones (Jones et al)
Briefly, 150 ul extract or external standards were added into a 1.5 ml eppendorf tube followed by addition of 20 pl y-glu-glu internal standard and 50 pl IAA added followed by mixing. The solution was adjusted to pH ~10 (purple color) by using KOH-KHCO3 working solution. Solutions were incubated 1 hr. under room temperature in the dark. Sanger's reagent was added at the same volume as of the total volume and the solution was incubated overnight (20hrs) in the dark at room temperature.
After incubation, the solution was centrifuged at 12000 rpm for 5 minutes with the supernatant transferred into another 1.5 ml eppendorf tube. 200 pl supernatant was added into an amber autovial which had a 300 pl inlet, fix the top with a crimper for HPLC analysis.
Solvents and separation conditions were as described (Fariss,
Jones). Levels of GSH and GSSG were quantified relative to authentic standards. Gamma-glutamyl-glutamate was used as an internal standard to assess derivatization efficiency. x Comparison of values for clinical chemistry, hematology and body weights vs baseline were analyzed by way of paired t-test on
SAS for windows with significance set at P<0.05. Means of values at each measured time point were separated by a one-way ANOVA with significance set at P<0.05. The difference in GSH:GSSG between day 84 and baseline were analyzed between groups by way of SAS for windows in a one-way ANOVA with significance sct at P<0.05.
Results
Concentrations of lipoic acid (ppm) in food as determined over 7 successive assays (0, 28, 56, 84, 112, 140, 168 days) were within the range of expected assay sensitivity and production parameters typically encountered at our facility (Table 1).
The food intake data were unremarkable. Most animals in all groups ingested more food at 6 months, on average, than at the beginning of the study. Body weight data were unremarkable except that some weight loss occurred initially in the 4500 ppm inclusion group but that change appeared to reversed by 6 months time. Body condition scores did not appear to be affected by this minor loss of weight.
The routine physical examinations did not reveal any evidence of nutrition related abnormalities or dl-alpha-lipoic acid toxicity. All animals in the study population remained normal during the entire course of the study. Occasional vomiting was observed in several animals during the course of the study; however, a trend was not observed that would lead one to the conclusion that the vomiting may be attributable to lipoic acid. One animal, in the highest inclusion group, was dropped from the study at day 21 for weight loss and leukocytosis. The leukocytosis in this animal had not resolved by the end of the study and is suspected to be attributable to some other disease process.
When serum biochemistry values for days 28, 56, 84, 112, 140, and 168 were compared with the initial values for the same group of dogs, several statistical differences were noted, however, none of these were considered biologically significant because these values were within or very near the laboratory reference range and consistent trends over months were noted. Comparisons between the controls and the other treatment groups at each time period also revealed several statistical differences, however, none of these were considered biologically significant because these values were within or very near the clinical laboratory reference ranges and no trends were present.
When the hematology values for days 28, 56, 84, 112, 140 and 168 were compared with the initial values for the same group of dogs, several statistical differences were noted; however, none of these were considered biologically significant because these values were within or very near the laboratory reference range and not trends were present.
Comparison between the controls and the other treatment groups at each time period revealed several statistical differences; however, none of these were considered biologically significant because these values were within or very near the clinical laboratory reference ranges and no trends were present.
GSH:GSSG ratio
The change in GSH:GSSG ratio over 84 days of feeding displayed a significant overall effect of diet (P=.024) with all . supplemented groups having an increase in the ratio (Table 2).
ANOVA revealed a significant difference, compared to the basal food, ‘ for the lowest and highest inclusions, however, the largest numerical increase was in the lowest inclusion level. That is to say, the changes in the GSH:GSSG ratio for the highest and lowest inclusion were significantly different from the change observed over this same time period in the basal food. Ratios for 4 points could not be determined at day 84 as no GSSG was detectable in any of these samples (1 control, 3 treatment groups). As such, the values for supplemented groups may have displayed even higher ratios of GSH:GSSG if the assay had been sensitive enough to detect the low levels of GSSG at day 84.
Table 1
Inclusion Rate Standard Percent
IEC NC CA NL
I EL IL
Ew we | mo | %
Table 2
Change in mean ratio of GSH:GSSG from day O to day 84 in dogs } consuming dl-alpha lipoic acid in an extruded food.
Difference in GSH:GSSG ratio-d O to d 84 compared to baseline food P value (opm | osm 6 05] open | mer 66 *1 dog in the control and 4500 ppm group had no detectable GSSG at day 84 while 2 dogs in the 3000 ppm group had no detectable GSSG at day 84.
Further observations with respect to alpha lipoic acid are applicable. Chronic feeding of alpha lipoic acid in diet is safe and effective. It improves the reduced glutathione (GSH) to oxidized glutathione (GSSG) ratio. The chronic administration of alpha lipoic acid in the diet can be for periods of one, two, three, four, five, or six months minimum up through a period of one, two, three, four, five years or even more including the lifetime of the animal. The alpha lipoic acid functions without any special protection in the diet such as encapsulation and need not be present in the diet in a unit dosage form such as those used in pharmaceuticals for example, tablet, pill, capsule and the like. The lipoic acid is provided in the diet in a minimum of about 25, 50, 75, or 100 ppm of diet. The uppermost range is just below its toxic level, all the way down to about 400, 300,
or 200 ppm of diet.
Generally, one does not go beyond about 6 or 7 mg/kg body weight of animal per day, more generally not above about 5. The alpha lipoic acid improves antioxidant defense capabilities as well as improves the animal's ability to resist oxidative damage.
All this is done with the proper quantities of other antioxidants present such as Vitamin E and Vitamin C.
This demonstrates that the action of alpha lipoic acid is beyond that of Vitamin C and/or Vitamin E.
Claims (27)
1. A companion pet diet meeting ordinary nutritional requirements for an adult pet and further comprising a sufficient amount of an antioxidant or mixture thereof, to inhibit the onset of deterioration of the mental capacity of said companion pet in aged years.
2. The diet in accordance with claim 1 wherein the pet is a canine.
3. The diet in accordance with claim 2 wherein the canine is 1 to 6 years.
4. The diet in accordance with claim 1 wherein the pet is a feline.
5. The diet in accordance with claim 4 wherein the feline is 1 to 6 years.
6. The diet in accordance with claim 1 wherein Vitamin E is present in at least about 100 ppm of the diet.
7. The diet in accordance with claim 6 wherein an antioxidant selected from the group consisting of Vitamin C, l-carnitine, alpha-lipoic acid or mixture thereof is present in the diet.
8. The diet of claim 1 wherein an antioxidant selected from the group consisting of Vitamin C, l-carnitine, alpha-lipoic acid or mixtures thereof is present in the diet.
9. The diet of claim 8 wherein at least about 50 ppm of Vitamin C are in the diet. ~ v
10. The diet of claim 8 wherein at least about 25 ppm of alpha- lipoic acid are in the diet.
11. The diet of claim 8 wherein at least about 50 ppm of l-carnitine are present in the diet.
12. A method for inhibiting the onset of deterioration of the mental capacity of an aged companion pet which comprises feeding said pet in its adult years a sufficient amount of an antioxidant or mixture thereof, to accomplish this inhibition.
13. The method in accordance with claim 12 wherein the pet is a canine.
14. The method in accordance with claim 13 wherein the canine is 1 to 6 years.
15. The method in accordance with claim 12 wherein the pet is a feline.
16. The method in accordance with claim 15 wherein the feline is at least 1 to 6 years.
17. The method in accordance with claim 12 wherein Vitamin E is fed to the pet in at least about 100 ppm as measured by the ) diet.
18. The method in accordance with claim 17 wherein an antioxidant selected from the group consisting of Vitamin C, 1- carnitine, alpha-lipoic acid or mixture thereof is fed to the pet.
19. The method of claim 12 wherein an antioxidant selected from the group consisting of Vitamin C, l-carnitine, alpha-lipoic acid or mixtures thereof is fed to the pet.
20. The method of claim 19 wherein at least about 50 ppm of Vitamin C are in the diet.
21. The method of claim 19 wherein at least about 25 ppm of alpha- lipoic acid are in the diet.
22. The method of claim 19 wherein at least about 50 ppm of 1- carnitine are present in the diet.
23. A companion pet diet meeting ordinary nutritional requirements of an adult pet and further comprising at least about 100 ppm of Vitamin E, at least about 50 ppm of Vitamin C, at least about ppm of alpha-lipoic acid and at least about 50 ppm of 1- carnitine in the diet.
24. The diet in accordance with claim 23 wherein the adult pet is a 25 canine of 1 to 6 years. :
25. The diet in accordance with claim 23 wherein the adult pet is a feline of 1 to 6 years.
26. A method for increasing the mental capacity of an adult companion pet, which comprises feeding the pet an amount of an antioxidant or mixture thereof sufficient to increase the mental capacity of said pet. »
27. A companion pet diet meeting ordinary nutritional requirements of an adult pet and further comprising an amount of an antioxidant or mixture thereof sufficient to increase the mental capacity of said pet.
28. A method for improving a companion pet's ability in its aged years to resist oxidative damage which comprises feeding said pet in its adult years a diet meeting nutritional requirement, said diet having at least about 25 ppm lipoic acid and said diet being fed for at least one month.
29. A method for improving a companion pet's ability in its aged year to resist oxidative damage which comprises feeding said pet in its aged year a diet meeting nutritional requirement, said diet having at least about 25 ppm lipoic acid and said diet being fed for at least one month.
@ PCT/US01/49654
32. Use in accordance with claim 31 wherein the pet is a canine.
33. Use in accordance with claim 32 wherein the canine is 1 to 6 years.
34. Use in accordance with claim 31 wherein the pet is a feline.
35. Use in accordance with claim 34 wherein the feline is at least 1 to 6 years.
36. Use in accordance with claim 31 wherein Vitamin E is fed to the pet in at least about 100 ppm as measured by the diet.
37. Use in accordance with claim 36 wherein an antioxidant selected from the group consisting of Vitamin C, l-carnitine, alpha-lipoic acid or mixture thereof is fed to the pet.
38. Use of claim 31 wherein an antioxidant selected from the group consisting of Vitamin C, l-carnitine, alpha-lipoic acid or mixtures thereof is fed to the pet.
39. Use of claim 38 wherein at least about 50 ppm of Vitamin C is in the diet.
40. Use of claim 38 wherein at least about 25 ppm of alpha-lipoic acid is in the diet. AMENDED SHEET
@ PCT/US01/49654
41. Use of claim 38 wherein at least about 50 ppm of l-carnitine is in the diet.
42. Use of an antioxidant or mixture thereof in the manufacture of a food for increasing the mental capacity of an adult companion pet, by feeding the pet an amount of said food sufficient to increase the mental capacity of said pet.
43. Use of at least about 25 ppm lipoic acid in the manufacture of a food for improving a companion pet’s ability in its aged years to resist oxidative damage by feeding said pet in its aged years said food in a diet meeting nutritional requirements for at least one month.
44. Use of at least about 25 ppm lipoic acid in the manufacture of a food for improving a companion pet’s ability in its aged years to resist oxidative damage by feeding said pet in its aged years said food in a diet meeting nutritional requirements for at least one month.
45. Food for use in a method for inhibiting the onset of deterioration of the mental capacity of an aged companion pet, said food comprising an antioxidant or mixture thereof, and said method comprising feeding said pet in its adult years a sufficient amount of said food to accomplish this inhibition.
46. Food for use in a method of treatment in accordance with claim 45 wherein the pet is a canine. AMENDED SHEET
@ PCT/US01/49654
47. Food for use in a method of treatment in accordance with claim 46 wherein the canine is 1 to 6 years.
48. Food for use in a method of treatment in accordance with claim 45 wherein the pet is a feline.
49. Food for use in a method of treatment in accordance with claim 48 wherein the feline is at least 1 to 6 years.
50. Food for use in a method of treatment in accordance with claim 45 wherein Vitamin E is fed to the pet in at least about 100 ppm as measured by the diet.
S51. Food for use in a method of treatment in accordance with claim 50 wherein an antioxidant selected from the group consisting of Vitamin C, l-carnitine, alpha-lipoic acid or mixture thereof is fed to the pet.
52. Food for use in a method of treatment of claim 45 wherein an antioxidant selected from the group consisting of Vitamin C, l-carnitine, alpha-lipoic acid or mixtures thereof is fed to the pet.
53. Food for use in a method of treatment of claim 52 wherein at least about 50 ppm of Vitamin C is in the diet.
54. Food for use in a method of treatment of claim 52 wherein at least about ppm of alpha-lipoic acid is in the diet. AMENDED SHEET
C : PCT/US01/49654
55. Food for use in a method of treatment of claim 52 wherein at least about 50 ppm of l-carnitine is present in the diet.
56. A food for use in a method for increasing the mental capacity of an adult companion pet, said food comprising an antioxidant or mixture thereof, and said method comprising feeding the pet an amount of said food sufficient to increase the mental capacity of said pet.
57. A food for use in a method for improving a companion pet’s ability in its aged years to resist oxidative damage, said food comprising at least about ppm lipoic acid, and said method comprising feeding said pet in its adult years said food in a diet meeting nutritional requirements for at least one month.
58. A food for use in a method for improving a companion pet’s ability in its aged years to resist oxidative damage, said food comprising at least about 25 ppm lipoic acid, and said method comprising feeding said pet in its aged years said food in a diet meeting nutritional requirements for at least one month.
59. A food for use in a method for increasing the learning capacity of an aged pet, said food comprising a composition having sufficient quantities of an antioxidant selected from the group consisting of Vitamin E, Vitamin C, lipoic acid and carnitine, and mixtures thereof, and said method comprising administering said food to said aged pet in an amount sufficient to increase the learning abilities of said aged pet. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24450400P | 2000-10-31 | 2000-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200303739B true ZA200303739B (en) | 2004-08-16 |
Family
ID=34078795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200303739A ZA200303739B (en) | 2000-10-31 | 2003-05-14 | Pet food composition and method. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200303739B (en) |
-
2003
- 2003-05-14 ZA ZA200303739A patent/ZA200303739B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007216836B2 (en) | Composition and method | |
US8592478B2 (en) | Antioxidant-containing food composition | |
US20110160299A1 (en) | Composition and method | |
US8592479B2 (en) | Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals | |
US20090156658A1 (en) | Antioxidant-Containing Food Composition For Use In Inhibiting Histamine Pathways In Companion Animals | |
CA2746769C (en) | Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals | |
DK2369946T3 (en) | Methods for increasing the palatability of feed compositions for domestic animals | |
AU2007216796B2 (en) | Composition and method | |
AU2002241634B2 (en) | Aged companion pet diet | |
ZA200303739B (en) | Pet food composition and method. | |
AU2002241634A1 (en) | Aged companion pet diet | |
JP2010142237A (en) | Composition and method |